IL282707A - Anti-tim-3 antibodies and their use - Google Patents

Anti-tim-3 antibodies and their use

Info

Publication number
IL282707A
IL282707A IL282707A IL28270721A IL282707A IL 282707 A IL282707 A IL 282707A IL 282707 A IL282707 A IL 282707A IL 28270721 A IL28270721 A IL 28270721A IL 282707 A IL282707 A IL 282707A
Authority
IL
Israel
Prior art keywords
tim
antibodies
Prior art date
Application number
IL282707A
Other languages
English (en)
Hebrew (he)
Inventor
Dong Zhang
Xinyan Zhao
Qi An
David Nannemann
Rinat Zaynagetdinov
Vanita D Sood
Christel Iffland
Original Assignee
Merck Patent Gmbh
Dong Zhang
Xinyan Zhao
Qi An
David Nannemann
Rinat Zaynagetdinov
Vanita D Sood
Christel Iffland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Dong Zhang, Xinyan Zhao, Qi An, David Nannemann, Rinat Zaynagetdinov, Vanita D Sood, Christel Iffland filed Critical Merck Patent Gmbh
Publication of IL282707A publication Critical patent/IL282707A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL282707A 2018-11-01 2021-04-27 Anti-tim-3 antibodies and their use IL282707A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862754383P 2018-11-01 2018-11-01
PCT/US2019/059555 WO2020093023A1 (en) 2018-11-01 2019-11-01 Anti-tim-3 antibodies

Publications (1)

Publication Number Publication Date
IL282707A true IL282707A (en) 2021-06-30

Family

ID=69159931

Family Applications (1)

Application Number Title Priority Date Filing Date
IL282707A IL282707A (en) 2018-11-01 2021-04-27 Anti-tim-3 antibodies and their use

Country Status (8)

Country Link
US (1) US20220081480A1 (cg-RX-API-DMAC7.html)
EP (1) EP3873611A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022505925A (cg-RX-API-DMAC7.html)
CN (1) CN113272017A (cg-RX-API-DMAC7.html)
AU (1) AU2019371457A1 (cg-RX-API-DMAC7.html)
CA (1) CA3117429A1 (cg-RX-API-DMAC7.html)
IL (1) IL282707A (cg-RX-API-DMAC7.html)
WO (1) WO2020093023A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7214440B2 (ja) * 2018-11-01 2023-01-30 三菱重工エンジニアリング株式会社 検証処理装置、検証処理方法及びプログラム
JPWO2023286854A1 (cg-RX-API-DMAC7.html) * 2021-07-16 2023-01-19
TW202327649A (zh) * 2021-09-15 2023-07-16 大陸商江蘇恆瑞醫藥股份有限公司 Pvrig/tigit結合蛋白聯合免疫檢查點抑制劑用於治療癌症
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
CN119654339A (zh) 2022-07-01 2025-03-18 特兰斯吉恩股份有限公司 包含表面活性蛋白-d和tnfsf成员的融合蛋白
WO2025202222A1 (en) 2024-03-25 2025-10-02 Institut National de la Santé et de la Recherche Médicale Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
WO2026059950A1 (en) * 2024-09-10 2026-03-19 Agilent Technologies, Inc. Anti-human tim3 antibodies for in vitro diagnostics

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
HRP20210977T1 (hr) 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
AU2015340056A1 (en) * 2014-10-27 2017-05-25 Agency For Science, Technology And Research Anti-TIM-3 antibodies
US20180153986A1 (en) * 2015-04-24 2018-06-07 The Brigham And Women's Hospital, Inc. Interactions between ceacam and tim family members
US20180207273A1 (en) * 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
PT3370768T (pt) * 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
US20190248893A1 (en) * 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
JOP20190013A1 (ar) * 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
MA50677A (fr) * 2016-11-01 2021-07-14 Anaptysbio Inc Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
TWI665216B (zh) * 2016-12-29 2019-07-11 財團法人生物技術開發中心 抗人類tim-3抗體及其使用方法
AU2018205401B2 (en) * 2017-01-09 2025-01-02 Tesaro, Inc. Methods of treating cancer with anti-TIM-3 antibodies
CN110050000B (zh) 2017-05-12 2022-07-26 苏州盛迪亚生物医药有限公司 含有TGF-β受体的融合蛋白及其医药用途

Also Published As

Publication number Publication date
JP2022505925A (ja) 2022-01-14
WO2020093023A1 (en) 2020-05-07
CN113272017A (zh) 2021-08-17
AU2019371457A1 (en) 2021-05-20
US20220081480A1 (en) 2022-03-17
EP3873611A1 (en) 2021-09-08
CA3117429A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
ZA202006904B (en) Anti-il-4r antibody and use thereof
IL282968A (en) Anti-NKG2A antibodies and their use
IL276950A (en) Anti-CD73 antibodies and uses thereof
SG11202105885WA (en) Anti-claudin antibodies and uses thereof
ZA202006066B (en) Anti-hla-g antibodies and use thereof
IL278846A (en) Anti-CD3 antibodies and uses thereof
SG11202100746WA (en) Anti-tigit antibody and use thereof
IL268206A (en) Antibodies directed against bcma and their use
IL275826A (en) Anti-mct1 antibodies and their uses
SG11202104240TA (en) Cll1-targeting antibody and application thereof
SG11202009772PA (en) Anti-dll3 antibodies and uses thereof
IL280321A (en) Antibodies against CXCR2 and their uses
IL276548A (en) Binding antibodies - BCMA and their uses
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
SG11202105161YA (en) Anti-il-27 antibodies and uses thereof
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof
ZA202100714B (en) Anti-npr1 antibodies and uses thereof
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
IL282708A (en) Anti-tim-3 antibodies and their use
IL277330A (en) Anti-IL-27 antibodies and uses thereof
SG11202012680TA (en) Anti-l1cam antibodies and uses thereof
IL283926B1 (en) Antibodies against alpha-synuclein and their uses
SG11202003585VA (en) Anti-vista antibody and use thereof
IL283890A (en) Anti-periostin antibodies and their uses
ZA201906248B (en) Anti-ceacam1 antibody and use thereof